QD 109
Alternative Names: QD-109Latest Information Update: 12 Jul 2022
At a glance
- Originator MingMed Biotechnology
- Developer MingMed Biotechnology; Zhuhai Qiwei Biotechnology
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dry eyes
Most Recent Events
- 12 Jul 2022 MingMed Biotechnology intends to license-out the product, in 2024 (MingMed Biotechnology website, July 2022)
- 12 Jul 2022 MingMed Biotechnology plans a phase II trial in Dry eyes in USA (Ophthalmic), in Q3 2022 (MingMed Biotechnology website, July 2022)
- 06 Jul 2022 Preclinical trials in Dry eyes in China (Ophthalmic), prior to July 2022 (Zhuhai Qiwei Biotechnology pipeline, July 2022)